Clinical bottom line
Emerging biomarker research in myelodysplastic syndromes (MDS) is advancing early detection and risk stratification beyond traditional morphologic and cytogenetic methods. Proteomic profiling, non-coding RNA signatures from extracellular vesicles, and mutation-driven molecular markers show promise as sensitive, minimally invasive tools to identify MDS at earlier stages and predict progression. While these novel biomarkers remain largely investigational, they offer potential to improve diagnostic accuracy and guide personalized therapeutic strategies. Integration into clinical practice awaits further validation in prospective cohorts and standardization of assays (Novak et al., 2026; Seddighi et al., 2025).
What the evidence shows
Novak et al. (2026) highlight proteomics as a frontier in MDS biomarker discovery, identifying protein expression patterns that correlate with disease subtypes and prognosis. Their work suggests that proteomic signatures may complement genetic and morphologic assessments to refine diagnosis.
Seddighi et al. (2025) systematically review extracellular vesicle-derived non-coding RNAs, including microRNAs and long non-coding RNAs, as circulating biomarkers in leukemias and pre-leukemic conditions such as MDS. These RNA species reflect the disease microenvironment and may serve as early indicators of clonal hematopoiesis and malignant transformation.
Swoboda et al. (2019) discuss mutation-driven therapy in MDS, underscoring the importance of detecting somatic mutations in genes involved in splicing, epigenetic regulation, and signaling pathways. Mutation profiling not only aids diagnosis but also informs targeted treatment approaches.
Brunner et al. (2020) emphasize aberrant RNA splicing as a key pathogenic mechanism in MDS, with splicing factor mutations representing both diagnostic markers and therapeutic targets.
Earlier foundational reviews by Schroeder et al. (2014) and Haas et al. (2014) provide context on the evolving understanding of MDS pathophysiology and the limitations of conventional diagnostic criteria, supporting the need for novel biomarkers.
Caveats and uncertainty
Most biomarker studies are exploratory with small sample sizes and heterogeneous patient populations.
Standardization of sample collection, processing, and assay platforms is lacking, limiting reproducibility.
Clinical utility in routine practice remains unproven without large prospective validation.
Overlap of biomarker profiles with other hematologic disorders may reduce specificity.
Cost and accessibility of advanced molecular and proteomic testing pose implementation challenges.
How this may change practice
Incorporation of proteomic and non-coding RNA biomarkers could enable earlier and more precise MDS diagnosis, particularly in patients with ambiguous cytopenias.
Molecular mutation profiling is increasingly important for risk stratification and guiding mutation-targeted therapies.
Liquid biopsy approaches may reduce need for invasive bone marrow biopsies in select cases.
Future diagnostic algorithms may integrate multi-omic data to personalize prognosis and treatment.
Clinicians should monitor emerging evidence and consider referral to specialized centers offering advanced biomarker testing.